T cell-based targeted immunotherapies for patients with multiple myeloma
Despite high-dose chemotherapy followed by autologs stem-cell transplantation as well as novel therapeutic agents, multiple myeloma (MM) remains incurable. Following the general trend towards personalized therapy, targeted immunotherapy as a new approach in the therapy of MM has emerged. Better prog...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2015
|
| In: |
International journal of cancer
Year: 2015, Jahrgang: 136, Heft: 8, Pages: 1751-1768 |
| ISSN: | 1097-0215 |
| DOI: | 10.1002/ijc.29190 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: http://dx.doi.org/10.1002/ijc.29190 Verlag, kostenfrei, Volltext: http://onlinelibrary.wiley.com/doi/10.1002/ijc.29190/abstract 
|
| Verfasserangaben: | Lei Wang, Nan Jin, Anita Schmitt, Jochen Greiner, Georg Malcherek, Michael Hundemer, Jiju Mani, Dirk Hose, Marc S. Raab, Anthony D. Ho, Bao-an Chen, Hartmut Goldschmidt and Michael Schmitt |
| Zusammenfassung: | Despite high-dose chemotherapy followed by autologs stem-cell transplantation as well as novel therapeutic agents, multiple myeloma (MM) remains incurable. Following the general trend towards personalized therapy, targeted immunotherapy as a new approach in the therapy of MM has emerged. Better progression-free survival and overall survival after tandem autologs/allogeneic stem cell transplantation suggest a graft versus myeloma effect strongly supporting the usefulness of immunological therapies for MM patients. How to induce a powerful antimyeloma effect is the key issue in this field. Pivotal is the definition of appropriate tumor antigen targets and effective methods for expansion of T cells with clinical activity. Besides a comprehensive list of tumor antigens for T cell-based approaches, eight promising antigens, CS1, Dickkopf-1, HM1.24, Human telomerase reverse transcriptase, MAGE-A3, New York Esophageal-1, Receptor of hyaluronic acid mediated motility and Wilms' tumor gene 1, are described in detail to provide a background for potential clinical use. Results from both closed and on-going clinical trials are summarized in this review. On the basis of the preclinical and clinical data, we elaborate on three encouraging therapeutic options, vaccine-enhanced donor lymphocyte infusion, chimeric antigen receptors-transfected T cells as well as vaccines with multiple antigen peptides, to pave the way towards clinically significant immune responses against MM. |
|---|---|
| Beschreibung: | Online 8 September 2014 Gesehen am 11.07.2017 |
| Beschreibung: | Online Resource |
| ISSN: | 1097-0215 |
| DOI: | 10.1002/ijc.29190 |